# HealthCare Royalty Partners

> HealthCare Royalty Partners is a VC fund backing Biotechnology. See 30 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Stamford, United States
- Total investments: 30
- Last investment: Jul 2026
- Lead investor: 70%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/healthcare-royalty-partners
- Website: http://www.healthcareroyalty.com

HealthCare Royalty Partners is a VC fund in Stamford focused on Biotechnology and Health Care. We are a $3.0+ billion global healthcare investment firm. We invest primarily in commercial stage healthcare product assets that have significant clinical value, strong barriers to entry and that are marketed by some of the world’s largest pharmaceutical companies. Over the past decade, our senior investment team has completed more than 60 royaltyinvestments valued in excess of $2.5 billion. For more information, visit www.healthcareroyalty.com.

## Contacts

5 contacts available for HealthCare Royalty Partners. Shizune tracks 4 team members at HealthCare Royalty Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/healthcare-royalty-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 17 | 57% |
| Health Care | 13 | 43% |
| Therapeutics | 11 | 37% |
| Medical | 7 | 23% |
| Medical Device | 6 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Debt | 13 | 43% |
| Private Equity | 3 | 10% |
| Series E | 2 | 7% |
| Debt Financing | 2 | 7% |
| Post-IPO Equity | 2 | 7% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 18 | 60% |
| France | 2 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Paul J Hadden | Senior Managing Director | 1 | https://shizune.co/investors/profile/paul-j-hadden |
| Christopher White | Chief Operating Officer | 0 | https://shizune.co/investors/profile/christopher-white-2 |
| Gregory B. Brown, MD | Founding Managing Director | 4 | https://shizune.co/investors/profile/gregory-b-brown-md |
| Thomas K. Conner | CFO | 0 | https://shizune.co/investors/profile/thomas-k-conner |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Spero Therapeutics | Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. | $105M | Post-IPO Debt | Jul 14, 2026 |  |
| BridgeBio | BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. | $1B | Post-IPO Equity | Jul 01, 2026 |  |
| Apnimed | Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has seriousconsequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.Apnimed, Inc. was founded in 2017 and is located in Cambridge, Massachusetts. | $50M | Debt Financing | Apr 06, 2026 |  |
| Esperion | Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Its prescription medicines focus on lowering elevated low-density lipoprotein cholesterol (LDL-C), a key factor in cardiovascular disease. The company offers oral, non-statin therapies that help reduce cardiovascular risk in patientswho are unable to tolerate or adequately respond to standard statin treatments. Its marketed products include bempedoic acid-based therapies that work by inhibiting ATP citrate lyase (ACLY), an enzyme involved in cholesterol synthesis. These medicines are designed to reduce LDL-C levels and support cardiovascular risk reduction in adults with conditions such as hyperlipidemia and atherosclerotic cardiovascular disease. | $50M | Post-IPO Debt | Mar 03, 2026 |  |
| Nanobiotix | Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnosticof cancer. | $50M | Post-IPO Debt | Oct 31, 2025 |  |
| Liquidia Technologies | Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $50M | Post-IPO Debt | Jun 23, 2025 |  |
| GENFIT | GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments.Their pioneering research is based on a strong heritage, stemmingfrom in-house knowledge and their desire to strive for excellence. Their drug discovery efforts are based on selecting specific nuclear receptors as targets and utilizing rational drug design to optimize their drug candidates.This strong skill base associated to their scientific and clinical expertise, translational disease-driven approach and strong bioinformatics capabilities, have allowed us to build a solid scientific platform enabling us to discover and develop their drug candidates and diagnostic tools. Professor Bart Staels, a world-renowned expert in nuclear receptors, co-founded GENFIT and has played a key role in shaping their company’s expertise over the years. Today, he sits as chair of the Scientific Advisory Board, lending decades of experience and essential know-how, supporting their role as an innovative leader in the discovery of solutions for the metabolic field. | $135.2M | Post-IPO Debt | Jan 30, 2025 |  |
| Esperion | Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Its prescription medicines focus on lowering elevated low-density lipoprotein cholesterol (LDL-C), a key factor in cardiovascular disease. The company offers oral, non-statin therapies that help reduce cardiovascular risk in patientswho are unable to tolerate or adequately respond to standard statin treatments. Its marketed products include bempedoic acid-based therapies that work by inhibiting ATP citrate lyase (ACLY), an enzyme involved in cholesterol synthesis. These medicines are designed to reduce LDL-C levels and support cardiovascular risk reduction in adults with conditions such as hyperlipidemia and atherosclerotic cardiovascular disease. | $250M | Post-IPO Debt | Dec 13, 2024 |  |
| Liquidia Technologies | Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $67.5M | Post-IPO Equity | Sep 11, 2024 |  |
| TG Therapeutics | TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101(ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX". | $250M | Post-IPO Debt | Aug 06, 2024 |  |

10 of 30 investments shown.

## Co-investors
- [Accuitive Medical Ventures](https://shizune.co/investors/profile/accuitive-medical-ventures) — VC Fund, 3 deals together
- [Athyrium Capital Management LP](https://shizune.co/investors/profile/athyrium-capital-management) — VC Fund, 3 deals together
- [Bausch & Lomb](https://shizune.co/investors/profile/bausch-lomb) — VC Fund, 3 deals together
- [Medtronic](https://shizune.co/investors/profile/medtronic) — VC Fund, 3 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 3 deals together
- [The Carlyle Group](https://shizune.co/investors/profile/the-carlyle-group) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does HealthCare Royalty Partners invest in?

HealthCare Royalty Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Debt and Private Equity stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact HealthCare Royalty Partners?

Public channels for HealthCare Royalty Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HealthCare Royalty Partners?

The team at HealthCare Royalty Partners includes Paul J Hadden (Senior Managing Director), Christopher White (Chief Operating Officer) and Gregory B. Brown, MD (Founding Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co